#Coronavirus Disease Research #References (AMEDEO, September 13 '26)

 

Eur J Radiol

1. GARCIA-HIDALGO C, Naval-Baudin P, Garcia-Garcia JI, Viveros-Castano M, et al
   Dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) vascular and metabolic biomarkers for presurgical diagnosis of adult brain tumors across different acquisition parameters.
   Eur J Radiol. 2026;205:113218.
   PubMed         Abstract available
   
   

   
   J Infect

2. QIAN J, Zhang Z, Zhang L
   SARS?CoV?2 spike CTD suppresses host metabolism but restricts viral entry through a PDZ?dependent trade?off.
   J Infect. 2026 Sep 11:106857. doi: 10.1016/j.jinf.2026.106857.
   PubMed        
   
   
3. MAZARAKIS N, Toh ZQ, Neal E, Nguyen C, et al
   Corrigendum to 'Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia' [J Infect 92 (2026)/106727].
   J Infect. 2026;93:106851.
   PubMed        
   
   
4. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
   Corrigendum to "The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose" [J Infect 90 (2025)/106447].
   J Infect. 2026;93:106850.
   PubMed        
   
   

   
   J Med Virol

5. TIKHONOVA IV, Dyukina AR, Grinevich AA, Tutukina MN, et al
   Immunological Properties of SARS-CoV-2 S and M Protein Fragments and Their Effects on Respiratory Burst in Human Neutrophils.
   J Med Virol. 2026;98:e71151.
   PubMed         Abstract available
   
   
6. SREELAKSHMI PR, Wagh P, Sarje P, Shinde T, et al
   Distinct Cytokine Signatures and Antibody Neutralization Capacity Differentiate Post-Acute Sequelae of COVID-19 From Recovered Individuals Despite Comparable T Cell Responses.
   J Med Virol. 2026;98:e71145.
   PubMed         Abstract available
   
   

   
   J Travel Med

7. VAN GENDEREN PJJ, van Sprang ENM
   Artificial Intelligence and Complementary Digital Health Technologies Across the Travel Medicine Continuum: A Narrative Review.
   J Travel Med. 2026 Sep 9:taag082. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

8. KIRK J, Sives S, Rayment A, Tappin A, et al
   Spike protein derived from an apathogenic IBV strain confers attenuated phenotype to a nephropathogenic IBV strain.
   J Virol. 2026 Sep 10:e0110326. doi: 10.1128/jvi.01103.
   PubMed         Abstract available
   
   
9. LIU M, Duong MTH, Laocharoensuk T, Aryal B, et al
   Mutations in the macrodomain 1 of nsp3 attenuate PEDV virulence in vivo without impairing in vitro replication.
   J Virol. 2026 Sep 9:e0125126. doi: 10.1128/jvi.01251.
   PubMed         Abstract available
   
   
10. YU R, Zhang L, Zhou P, Zhang Z, et al
    Low-pH-induced conformational changes in the spike protein promote porcine deltacoronavirus infection by enhancing viral binding efficiency to the porcine aminopeptidase receptor.
    J Virol. 2026 Sep 9:e0116826. doi: 10.1128/jvi.01168.
    PubMed         Abstract available
    
    
11. ALVARADO RE, Chen J, Lokugamage KG, Zhou Y, et al
    Antagonism of stress granules is key to SARS-CoV-2 infection and pathogenesis.
    J Virol. 2026 Sep 8:e0099226. doi: 10.1128/jvi.00992.
    PubMed         Abstract available
    
    
12. YAO Z, Zhu Y, Liu N, Hu Y, et al
    The alpha-helix-facilitating amino acid sequence EAAAK dramatically increases the antiviral activity of SARS-CoV-2 fusion-inhibitory peptides via the endosome fusion pathway.
    J Virol. 2026 Sep 8:e0106726. doi: 10.1128/jvi.01067.
    PubMed         Abstract available
    
    

    
    Life Sci

13. HAN D, Beurel E
    The spike protein S1 of SARS-CoV-2 promotes Th17 cell-dependent stress-induced depressive-like behaviors in mice.
    Life Sci. 2026 Sep 8:124672. doi: 10.1016/j.lfs.2026.124672.
    PubMed         Abstract available
    
    

    
    N Engl J Med

14. HAYDEN FG, Sax PE
    Ensitrelvir for Covid-19 Postexposure Prophylaxis. Reply.
    N Engl J Med. 2026;395:1039.
    PubMed        
    
    
15. SUZUKI J, Imai H, Endo S
    Ensitrelvir for Covid-19 Postexposure Prophylaxis.
    N Engl J Med. 2026;395:1039.
    PubMed        
    
    

    
    Travel Med Infect Dis

16. TIMPERLEY EK, Swithenbank L, Beeching NJ, Tang E, et al
    General physicians still fail to take travel histories.
    Travel Med Infect Dis. 2026 Sep 9:103021. doi: 10.1016/j.tmaid.2026.103021.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, Sept. 5 '26)

 

BMJ

1. YANG YT
   Covid-19 vaccine study: scientific asylum should never have been necessary.
   BMJ. 2026;394:e100738.
   PubMed        
   
   

   
   Clin Infect Dis

2. TIPPETT A, Prasad PV, Begier E, Kim SS, et al
   Respiratory Syncytial Virus Hospitalizations in Adults >/=50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.
   Clin Infect Dis. 2026;83:e416-e426.
   PubMed         Abstract available
   
   
3. GODWIN P, Shvachko V, Oppelt T, Wang CY, et al
   Retrospective Cohort Study Assessing Remdesivir Effectiveness in Hospitalized COVID-19 Patients With Renal or Hepatic Comorbidities.
   Clin Infect Dis. 2026 Sep 1:ciag534. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. THUNDAKATTIL AV, Prabhu R, Prabhu G, Mani M, et al
   Mixing versus matching booster vaccines: A longitudinal humoral immune kinetics against Omicron in a Malaysian cohort.
   Int J Infect Dis. 2026 Sep 4:109103. doi: 10.1016/j.ijid.2026.109103.
   PubMed         Abstract available
   
   
5. JIN M, Xin H, Zhang J, Huang X, et al
   Epidemiological Characteristics of Scarlet Fever in Liaoning Province, China: A Pre- and Post-Pandemic Comparison, 2005-2024.
   Int J Infect Dis. 2026 Sep 4:109081. doi: 10.1016/j.ijid.2026.109081.
   PubMed         Abstract available
   
   
6. KIM JS, Park JH, Kim J, Lee YC, et al
   Non-invasive aspergillosis following COVID-19 exacerbates the severity of SARS-CoV-2 infection.
   Int J Infect Dis. 2026 Sep 3:109095. doi: 10.1016/j.ijid.2026.109095.
   PubMed         Abstract available
   
   
7. XUE M, Zhou Z, Chao Y, Li J, et al
   Influenza A-Associated Pulmonary Aspergillosis in Critically Ill Patients in the Post-COVID-19 Era: A Multicenter Cohort Study from China.
   Int J Infect Dis. 2026 Aug 29:109089. doi: 10.1016/j.ijid.2026.109089.
   PubMed         Abstract available
   
   

   
   Intensive Care Med

8. MEZA-FUENTES G, Delgado I, Vial PA, Godoy-Faundez A, et al
   Temporal trends in critical care burden and outcomes of Andes virus-associated hantavirus cardiopulmonary syndrome: a national Chilean cohort.
   Intensive Care Med. 2026 Sep 2. doi: 10.1007/s00134-026-08599.
   PubMed         Abstract available
   
   

   
   J Infect

9. LOUBET P, Roubille F, Launay O, Fourati S, et al
   Cardiovascular outcomes and acute human metapneumovirus infection in adults: A systematic literature review.
   J Infect. 2026;93:106843.
   PubMed         Abstract available
   
   
10. WALKER JL, Ribeiro S, Litt D, Patel T, et al
    Antenatal pertussis vaccine effectiveness in England remains high post COVID-19.
    J Infect. 2026;93:106836.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. FERRENA A, Schlamp F, Tuen M, Duerr R, et al
    Durable Interferon-Linked Blood Signatures During COVID-19 Convalescence.
    J Med Virol. 2026;98:e71133.
    PubMed         Abstract available
    
    

    
    J Virol

12. HU L, Tian R, Gao L, Xu N, et al
    PEDV envelope protein promotes viral replication by remodeling host iron homeostasis via the TRIM28-KLF15-FPN axis.
    J Virol. 2026 Sep 2:e0123926. doi: 10.1128/jvi.01239.
    PubMed         Abstract available
    
    
13. DARNLEY JA, Waller SJ, French RK, Parata R, et al
    Divergent coronaviruses discovered in the virome of lamprey with reddening syndrome.
    J Virol. 2026 Sep 2:e0064526. doi: 10.1128/jvi.00645.
    PubMed         Abstract available
    
    

    
    JAMA

14. LIPSON RA, Senerth E, Watson MA, Saini H, et al
    COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.
    JAMA. 2026 Sep 2. doi: 10.1001/jama.2026.18191.
    PubMed         Abstract available
    
    
15. SENERTH E, Sheikholeslamian SM, Sivakumaran K, Watson MA, et al
    Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.
    JAMA. 2026 Sep 2. doi: 10.1001/jama.2026.18126.
    PubMed         Abstract available
    
    
16. ROTEN L, Maurhofer J, Krisai P, Breitenstein A, et al
    Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation: The PIFPAF-PFA Randomized Clinical Trial.
    JAMA. 2026 Aug 29:e2617598. doi: 10.1001/jama.2026.17598.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

17. BADEN LR, Shah NS, Liu STH, Cohen J, et al
    Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Infect Dis. 2026 Aug 31:S1473-3099(26)00406.
    PubMed         Abstract available
    
    

    
    Nature

18. MAKIN S
    When do infections lead to long COVID? Scientists close in on triggers and treatments for post-viral syndromes.
    Nature. 2026;657:26-28.
    PubMed 

#Coronavirus Disease Research #References (AMEDEO, August 29 '26)

 

Antiviral Res

1. PU F, Guo Y, Pan X, Liu X, et al
   Dual-targeting engineered binding proteins block SARS-CoV-2 infection and complement activation.
   Antiviral Res. 2026;254:106515.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. TRAUTNER BW, Cortes-Penfield NW, Gupta K, Hirsch EB, et al
   Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI.
   Clin Infect Dis. 2025 Dec 19:ciaf460. doi: 10.1093.
   PubMed        
   
   
3. TRAUTNER BW, Cortes-Penfield NW, Gupta K, Hirsch EB, et al
   Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI.
   Clin Infect Dis. 2025 Dec 19:ciaf461. doi: 10.1093.
   PubMed        
   
   

   
   Infect Control Hosp Epidemiol

4. PRAKASH-ASRANI R, Shioda K, Bower CW, Steinberg JP, et al
   Impact of hand hygiene on the detection of multidrug-resistant organisms and other pathogens of epidemiologic significance after implementation of an automated hand hygiene monitoring system.
   Infect Control Hosp Epidemiol. 2026 Aug 27:1-7. doi: 10.1017/ice.2026.10524.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. WAGATSUMA K, Song Z, Lam TTY, Kwok KO, et al
   Changes in respiratory virus seasonality across the COVID-19 pandemic: a multicentre comparative study in Leicester, Rotterdam, Hong Kong, and Christchurch.
   Int J Infect Dis. 2026 Aug 27:109080. doi: 10.1016/j.ijid.2026.109080.
   PubMed         Abstract available
   
   
6. RAGHUVAMSI PV, Loh SB, Bhattacharya P, Ho J, et al
   Investigating the effectiveness of multimodal data in forecasting SARS-COV-2 case surges.
   Int J Infect Dis. 2026 Aug 25:109062. doi: 10.1016/j.ijid.2026.109062.
   PubMed         Abstract available
   
   

   
   J Infect

7. SANDERSON ND, Dingle KE, Hopkins KMV, Vaughan A, et al
   Clinical validation of an optimised metagenomic nanopore sequencing method for detecting viral respiratory pathogens.
   J Infect. 2026 Aug 22:106839. doi: 10.1016/j.jinf.2026.106839.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. LI J, Song W, Li J, Peng R, et al
   Enhanced Immunogenicity and Cross-Neutralizing Activity of a Trivalent Adenoviral Vector-Based SARS-CoV-2 Vaccine in Mice.
   J Med Virol. 2026;98:e71119.
   PubMed         Abstract available
   
   

   
   J Virol

9. LIU G, Chen J, Wu F, Wei P, et al
   Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects.
   J Virol. 2026 Aug 28:e0059926. doi: 10.1128/jvi.00599.
   PubMed         Abstract available
   
   
10. STADLER E, Mordant F, Gartner M, Docken SS, et al
    Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assays.
    J Virol. 2026 Aug 27:e0082326. doi: 10.1128/jvi.00823.
    PubMed         Abstract available
    
    
11. DE BEIJER NL, Limpens RWAL, Barcena M, Snijder EJ, et al
    Conserved structural features of RNA export pores spanning the double membrane of arterivirus and coronavirus replication organelles.
    J Virol. 2026 Aug 26:e0085926. doi: 10.1128/jvi.00859.
    PubMed         Abstract available
    
    
12. KUMAR S, Lai L, Ellis ML, Patel A, et al
    Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.
    J Virol. 2026 Aug 26:e0074926. doi: 10.1128/jvi.00749.
    PubMed         Abstract available
    
    

    
    JAMA

13. CHUNG TH, Raj SR
    Postural Orthostatic Tachycardia Syndrome (POTS): A Review.
    JAMA. 2026 Aug 24. doi: 10.1001/jama.2026.14809.
    PubMed         Abstract available
    

#Coronavirus Disease Research #References (AMEDEO, August 22 '26)

 

Antiviral Res

1. YURGELONIS I, Rai DK, Lee JT, Li Z, et al
   Antiviral activity of nirmatrelvir against contemporary SARS-CoV-2 variants.
   Antiviral Res. 2026;254:106517.
   PubMed         Abstract available
   
   
2. MALUNE P, Kullik G, Jia X, Bandowski G, et al
   gamma-Monoalkyl triphosphate analogues of acyclic nucleoside phosphonates inhibit SARS-CoV-2 replication in vitro by inducing dissociation of the minimal replication-transcription complex.
   Antiviral Res. 2026;254:106514.
   PubMed         Abstract available
   
   
3. ZOU J, Su L, Lu J, Jing H, et al
   Oligomerized receptor binding domain blocks pan-sarbecovirus infection via enhanced avidity to host receptor.
   Antiviral Res. 2026;254:106516.
   PubMed         Abstract available
   
   

   
   BMJ

4. O'DOWD A
   Covid-19: 40% of affected healthcare workers had long covid, and a quarter still had symptoms after a year.
   BMJ. 2026;394:e100628.
   PubMed        
   
   

   
   Clin Infect Dis

5. RUBIS AB, Youngkin E, Firmender P, Argueta G, et al
   Updated Assessment of the Impact of the Modified Council of State and Territorial Epidemiologists Case Definition for Pertussis on Reported Pertussis.
   Clin Infect Dis. 2026 Aug 22:ciag515. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

6. PINTO TF, Santoro A, de Oliveira ALG, Tavares TS, et al
   Risk of Post-acute Symptoms and Conditions After SARS-CoV-2 Compared to Other Respiratory Viral Infections: A Systematic Review and Meta-Analysis.
   Int J Infect Dis. 2026 Aug 21:109056. doi: 10.1016/j.ijid.2026.109056.
   PubMed         Abstract available
   
   
7. KHAN SMA, Irfan S, Ashraf J, Ghayas H, et al
   Molecularepidemiology and antimicrobial resistance determinants of Corynebacterium diphtheriae causing infections in Karachi, Pakistan, 2023-2024.
   Int J Infect Dis. 2026 Aug 20:109058. doi: 10.1016/j.ijid.2026.109058.
   PubMed         Abstract available
   
   
8. ANZAI A, Nishiura H
   Post-hoc evaluation of travel restrictions during the COVID-19 pandemic in Japan, 2020-2022.
   Int J Infect Dis. 2026 Aug 17:109068. doi: 10.1016/j.ijid.2026.109068.
   PubMed         Abstract available
   
   
9. RAHMOUN MA, Sabate-Elabbadi A, Brun-Buisson C, Watier L, et al
   Impact of the COVID-19 pandemic on the association between sepsis etiology and mortality among ICU patients in France.
   Int J Infect Dis. 2026 Aug 16:109060. doi: 10.1016/j.ijid.2026.109060.
   PubMed         Abstract available
   
   
10. LEAO V, Assad Z, Valtuille Z, Ouldali N, et al
    Shifts in unidentified-pathogen acute hematogenous osteomyelitis incidence after non-pharmaceutical interventions highlight the role of seasonal viruses: an interrupted time-series analysis.
    Int J Infect Dis. 2026 Aug 16:109054. doi: 10.1016/j.ijid.2026.109054.
    PubMed         Abstract available
    
    
11. PENG B, Allen-Benson D, Talebi Y, Ghosh S, et al
    Temporal, Demographic, and Geographic Patterns of Long COVID Incidence in Relation to SARS-CoV-2 Variant Emergence: Insights from the Texas All-Payer Claims Database (TX-APCD).
    Int J Infect Dis. 2026 Aug 16:109051. doi: 10.1016/j.ijid.2026.109051.
    PubMed         Abstract available
    
    
12. AZHAR EI, Alqahtani M, Assiri AM, Al-Abri SS, et al
    MERS-CoV in the Middle East and Africa: from surveillance gaps in humans and dromedary camels to One Health frameworks for spillover, prevention, research and response preparedness.
    Int J Infect Dis. 2026 Aug 15:109046. doi: 10.1016/j.ijid.2026.109046.
    PubMed         Abstract available
    
    

    
    J Med Virol

13. FERRO V, Cozzolino C, Olita C, Severini F, et al
    Viral Landscape, Clinical Impact, and Management Trends in Hospitalized Children for Viral-Associated Lower Respiratory Tract Diseases: A Comparative Analysis of Two Post-Pandemic Seasons in Rome, Italy.
    J Med Virol. 2026;98:e71103.
    PubMed         Abstract available
    
    
14. HUANG Z, Liu W, Zhang N, Guo H, et al
    Respiratory Virus Immunological Dynamics in the Post-Pandemic Era of Southeastern China: A Retrospective Serological Investigation.
    J Med Virol. 2026;98:e71112.
    PubMed         Abstract available
    
    

    
    J Virol

15. ZHANG Y, Fujita S, Kajihara M, Changula K, et al
    Novel African Rhinolophus bat ACE2 sequences reveal the determinants of Afro-Eurasian sarbecovirus entry.
    J Virol. 2026 Aug 21:e0054026. doi: 10.1128/jvi.00540.
    PubMed         Abstract available
    
    
16. ZHENG Y, Luo D, Tian Q, Zhang M, et al
    TPPS4 inhibits PEDV by stabilizing viral RNA G-quadruplex and promoting ER stress: a transfer-learning-driven discovery.
    J Virol. 2026;100:e0077426.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

17. BASNYAT B, Adhikari S, Shrestha P, Budhathoki S, et al
    Azithromycin with or without cefixime for suspected or culture-confirmed uncomplicated typhoid fever in Nepal, Bangladesh, and Pakistan (ACT-South Asia): a double-blind, parallel-group, randomised, placebo-controlled, phase 4 trial.
    Lancet Infect Dis. 2026 Aug 20:S1473-3099(26)00358.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, August 16 '26)

 

BMJ

1. LANG K
   What do we know about covid-19 and smell loss?
   BMJ. 2026;394:e100155.
   PubMed        
   
   

   
   Int J Infect Dis

2. SEO G, Joo H, Song K, Kim M, et al
   Corrigendum to "Static and dynamic scoring systems for post-acute sequelae of SARS-CoV-2 in a Korean Cohort" [International Journal of Infectious Diseases Volume 164, 108378, March 2026].
   Int J Infect Dis. 2026;171:108980.
   PubMed        
   
   

   
   Intensive Care Med

3. DAOUD T, Villar J, Annane D
   Corticosteroids in ARDS: old controversies, new insights, and future directions.
   Intensive Care Med. 2026 Aug 13. doi: 10.1007/s00134-026-08567.
   PubMed         Abstract available
   
   

   
   J Infect

4. ZHOU S, Liu C, Liu W, Cai K, et al
   Cross-Neutralizing Antibody Responses to Diverse Coronaviruses in the Human Population.
   J Infect. 2026 Aug 11:106827. doi: 10.1016/j.jinf.2026.106827.
   PubMed         Abstract available
   
   

   
   J Med Virol

5. VIZGIRDA G, Underwood AP, Fahnoe U, Solund C, et al
   SARS-CoV-2 Neutralization Breadth Is Shaped by Variant Exposure and Immune History.
   J Med Virol. 2026;98:e71054.
   PubMed         Abstract available
   
   

   
   Lancet

6. SCHWARTZ CA, Weiss Y
   Hate has no place in medicine.
   Lancet. 2026;408:606.
   PubMed        
   
   

   
   Lancet Infect Dis

7. HE P, Song Y, Guo C, Yu L, et al
   Antibody evasion and receptor binding of SARS-CoV-2 variants PQ.16.1.1 and RK.1.
   Lancet Infect Dis. 2026 Aug 13:S1473-3099(26)00429.
   PubMed        
   

#Coronavirus Disease Research #References (AMEDEO, August 9 '26)

 

BMJ

1. YAMEY G, Titanji BK
   Fauci's Senate hearing riled up the MAGA base-but at the cost of damaging public health.
   BMJ. 2026;394:e100529.
   PubMed        
   
   
2. RUBINSTEIN F, Moraes Morelli D, Palma I, Sanjurjo M, et al
   Evaluation of patient centred digital adherence technology for tuberculosis treatment outcomes: pragmatic randomised controlled trial.
   BMJ. 2026;394:e100195.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

3. MUNBLIT D, Buonsenso D, Olliaro PL, Semple MG, et al
   Vaccines, Bias, and the Perils of Non-peer-reviewed Studies: Fueling Misinformation and Vaccine Hesitancy.
   Clin Infect Dis. 2026 Aug 5:ciag403. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect

4. LI X, Mercade-Besora N, Lam AS, Barboza C, et al
   Effectiveness and waning of the fourth dose mRNA COVID-19 vaccines for the prevention of SARS-CoV2 infection related hospitalisations and deaths.
   J Infect. 2026 Aug 5:106825. doi: 10.1016/j.jinf.2026.106825.
   PubMed         Abstract available
   
   

   
   J Med Virol

5. ACHARYA A, Thurman M, Sutar D, Olasunkanmi OI, et al
   In-Vitro Evaluation of HIV/SARS-CoV-2 Co-Infection Mediated Proteomic Changes in Astrocytes and Pericytes Reveals Altered Signaling Pathways Associated With Neurodegenerative Disorders.
   J Med Virol. 2026;98:e71086.
   PubMed         Abstract available
   
   

   
   J Virol

6. ZHANG L, Chen N, Eichmann A, Nehlmeier I, et al
   The conserved QTQTX motif in the SARS-CoV-2 spike protein is dispensable for cleavage and lung cell entry of the emerging variant BA.3.2.
   J Virol. 2026 Aug 5:e0069126. doi: 10.1128/jvi.00691.
   PubMed         Abstract available
   
   
7. HANRIEDER L, Schreiner S
   One virus-many strategies: type-specific interactions between human adenoviruses and innate immunity.
   J Virol. 2026 Aug 3:e0020426. doi: 10.1128/jvi.00204.
   PubMed         Abstract available
   
   

   
   Life Sci

8. ZANG R, Ren Y, Wang J, Le Z, et al
   SARS-CoV-2 nucleocapsid protein drives pulmonary injury by enhancing GRP75-dependent ER-mitochondria tethering and reprogramming of alveolar macrophages.
   Life Sci. 2026 Aug 8:124625. doi: 10.1016/j.lfs.2026.124625.
   PubMed         Abstract available
   
   

   
   N Engl J Med

9. BUTLER CC, Pinto AD, Little P
   Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients. Reply.
   N Engl J Med. 2026;395:622.
   PubMed        
   
   
10. KUMAR PD
    Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;395:622.
    PubMed        
    
    
11. PUZNIAK L, Hammond J
    Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;395:621.
    PubMed        
    
    

    
    Nat Ment Health

12. ZHOU T, Zhang B, Lu Y, Chen J, et al
    SSRI/SNRI and long COVID in children and adolescents with neuropsychiatric conditions: a cohort study from the RECOVER Initiative.
    Nat Ment Health. 2026;4:1275-1284.
    PubMed         Abstract available
    
    

    
    Nature

13. BUNDELL S, Petric Howe N
    Briefing Chat: Is DNA repair the secret to a long life? Whales and mole rats offer tantalizing hints.
    Nature. 2026 Aug 7. doi: 10.1038/d41586-026-02488.
    PubMed        
    
    
14. KOZLOV M
    COVID can wake up a slew of dormant viruses inside you.
    Nature. 2026 Aug 5. doi: 10.1038/d41586-026-02443.
    PubMed        
    
    
15. MAGUIRE C, Chen J, Rouphael N, Morse BA, et al
    Virus reactivation in acute and long COVID-19.
    Nature. 2026 Aug 5. doi: 10.1038/s41586-026-10740.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, August 1 '26)

 

Antiviral Res

1. WANG K, Gibbons JS, Bisht N, Reyes AC, et al
   SARS-CoV-2 resistance pathways to EDP-235.
   Antiviral Res. 2026;253:106493.
   PubMed         Abstract available
   
   

   
   Emerg Infect Dis

2. KIM S, Chun BC
   Kudoa septempunctata Parasite-Associated Foodborne Disease Outbreaks, South Korea, 2015-2024.
   Emerg Infect Dis. 2026;32:1373-1375.
   PubMed         Abstract available
   
   
3. XU Y, Xiong W, Huang X, Cowling BJ, et al
   Respiratory Syncytial Virus Suppression through Public Health and Social Measures, Hong Kong, China, 2020-2023.
   Emerg Infect Dis. 2026;32:1315-1318.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. SPILIOPOULOU A, Betaania L, Giannopoulou I, Leonidou L, et al
   Candidemia in Post-COVID Era: Increasing incidence of endemic fluconazole-resistant Candida parapsilosis and Candidozyma auris.
   Int J Infect Dis. 2026 Jul 30:109018. doi: 10.1016/j.ijid.2026.109018.
   PubMed         Abstract available
   
   
5. GARNERET P, Gaubert G, Nauleau S, Franke F, et al
   Social Deprivation and Remoteness as Determinant of COVID-19 Hospitalisations and Severity: an Area-Level Analysis in South-Eastern France.
   Int J Infect Dis. 2026 Jul 30:109013. doi: 10.1016/j.ijid.2026.109013.
   PubMed         Abstract available
   
   
6. GRIMM K, Hodel EM, Gasser L, Schuller S, et al
   Feasibility of studying respiratory infection transmission in a Swiss household cohort: Findings from the BEready ("Bern, get ready") study.
   Int J Infect Dis. 2026 Jul 29:109019. doi: 10.1016/j.ijid.2026.109019.
   PubMed         Abstract available
   
   
7. RAHAJAMANANA VL, Rabezanahary H, Arroyave A, Wantchecon A, et al
   Dynamics of neutralizing antibodies against enterovirus D68 in adults during the COVID-19 pandemic.
   Int J Infect Dis. 2026 Jul 27:109008. doi: 10.1016/j.ijid.2026.109008.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. MORETTO SL, Cassela PLCS, Trigo GL, Lozovoy MAB, et al
   Investigation of PDCD1 Gene Polymorphisms and Haplotypes in COVID-19 Severity and Outcome in a Brazilian Population.
   J Med Virol. 2026;98:e71090.
   PubMed         Abstract available
   
   
9. PASITTUNGKUL S, Vichaiwattana P, Poovorawan Y, Wanlapakorn N, et al
   Post-Pandemic Resurgence of Respiratory Syncytial Virus in Thailand: Molecular Epidemiology and Sublineage Turnover Among Children, 2023-2025.
   J Med Virol. 2026;98:e71089.
   PubMed         Abstract available
   
   
10. FRASCA F, Maddaloni L, D'Auria A, Fracella M, et al
    SARS-CoV-2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV.
    J Med Virol. 2026;98:e71067.
    PubMed         Abstract available
    
    
11. HUANG Y, Gao Y, Li Y, Song G, et al
    Application of a Super-Multiplex Microfluidic qPCR System for Detection of Respiratory Pathogens in Patients With Influenza-Like Illness.
    J Med Virol. 2026;98:e71072.
    PubMed         Abstract available
    
    

    
    J Virol

12. XU J, Chan H-w, Yang R, Wu X-R, et al
    Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells.
    J Virol. 2026 Jul 31:e0097126. doi: 10.1128/jvi.00971.
    PubMed         Abstract available
    
    
13. LIANG X, Chi X, Deng X
    Coronavirus Nsp15 endoribonuclease: linking viral RNA regulation to immune evasion and viral fitness.
    J Virol. 2026 Jul 31:e0170025. doi: 10.1128/jvi.01700.
    PubMed         Abstract available
    
    
14. ZENG W, Zhang G, Ma H, Xiong L, et al
    ACE2-fused nanobody targeting a cryptic RBD epitope broadly neutralizes SARS-like viruses.
    J Virol. 2026 Jul 30:e0060826. doi: 10.1128/jvi.00608.
    PubMed         Abstract available
    
    
15. HE L, Su Y-WN, Zhang F, Moustafa IM, et al
    Recovery of proofreading-impaired SARS-CoV-2 reveals a mutator phenotype and an ExoN activity threshold for viability.
    J Virol. 2026 Jul 29:e0080926. doi: 10.1128/jvi.00809.
    PubMed         Abstract available
    
    
16. DWIVEDI S, Kar S, Horton AP, Gollihar JD, et al
    ViralMap: predicting features in viral proteins from primary sequence.
    J Virol. 2026 Jul 28:e0075726. doi: 10.1128/jvi.00757.
    PubMed         Abstract available
    
    

    
    Nature

17. CHEN E
    Can long COVID be prevented? Two drugs finally show promise.
    Nature. 2026 Jul 29. doi: 10.1038/d41586-026-02341.
    PubMed        

#SARS-CoV-2 #Surveillance in Free-Ranging #Wildlife in New England and #Virginia, #USA, 2022–2025

 

Abstract

Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected a wide range of animal species, including wildlife. Although SARS-CoV-2 infection has been widely reported in wildlife, particularly in white-tailed deer (WTD; Odocoileus virginianus) across the United States, data on viral circulation in New England wildlife remain limited. Here, we investigated active SARS-CoV-2 infection and serological evidence of previous exposure in free-ranging wildlife from New England and Virginia. We examined samples from 1646 animals representing 29 wildlife species, collected through wildlife rehabilitation centers, clinics, and hunter harvests in New England and Virginia between 2022 and 2025. SARS-CoV-2 RNA was detected in three WTD from Massachusetts and Vermont. Phylogeographic analysis showed that the Vermont WTD SARS-CoV-2 sequences were closely related to contemporaneous human SARS-CoV-2 sequences from the same region, consistent with a possible human-to-deer spillover event. Serological screening by ELISA detected SARS-CoV-2 reactive samples in nine individuals from three species, including Eastern cottontail (Sylvilagus floridanus), Eastern coyote (Canis latrans), and raccoon (Procyon lotor), providing putative evidence of prior SARS-CoV-2 exposure. However, neutralizing antibodies against the SARS-CoV-2 Omicron variant were detected in only a single Eastern cottontail. Overall, these findings indicate sporadic SARS-CoV-2 detection and limited serological evidence of prior exposure among wildlife sampled in New England and Virginia, and highlight the importance of continued surveillance to detect spillover events, monitor viral evolution, and assess the potential risks associated with wildlife reservoirs.

Source: 

Link: https://www.mdpi.com/1999-4915/18/8/832

____

#Coronavirus Disease Research #References (AMEDEO, July 25 '26)

 

BMJ

1. 
   Addressing the indirect health burden of covid-19.
   BMJ. 2026;394:e100376.
   PubMed        
   
   
2. 
   Reduced disease detection during covid-19.
   BMJ. 2026;394:e100377.
   PubMed        
   
   

   
   Clin Infect Dis

3. ISKANDER JK, Haridopolos S
   Making Invisible Illnesses Visible: Recognizing and Responding to Infection-Associated Chronic Conditions.
   Clin Infect Dis. 2026;83:e58-e61.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

4. MCGILL E, Lee D, Quach C, Leis JA, et al
   Hospital characteristics associated with healthcare-associated viral respiratory infection rates in a Canadian acute care network.
   Infect Control Hosp Epidemiol. 2026 Jul 22:1-9. doi: 10.1017/ice.2026.10490.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. JO S, Min KD, Cho SI
   Counterfactual Evaluation of COVID-19 Control Policies in South Korea: A Scenario-Based Modeling Study.
   Int J Infect Dis. 2026 Jul 22:108997. doi: 10.1016/j.ijid.2026.108997.
   PubMed         Abstract available
   
   

   
   Intensive Care Med

6. EHRMANN S, Li J, Liu L, Guerin C, et al
   Prone positioning in ARDS.
   Intensive Care Med. 2026 Jul 20. doi: 10.1007/s00134-026-08543.
   PubMed         Abstract available
   
   

   
   J Infect

7. QUINOT C, Lunt R, Kirsebom F, Andrews N, et al
   Serological outcomes of SARS-CoV-2 infection by vaccination status and variant in England.
   J Infect. 2026;93:106819.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. ZUNIGA-HERNANDEZ ME, Reyes-Barrera KL, Hidalgo-Figueroa SN, Paez-Perez ED, et al
   ACE2- and HR2-Mimetic Peptides Inhibit Replication of Two SARS-CoV-2 Variants.
   J Med Virol. 2026;98:e71060.
   PubMed         Abstract available
   
   
9. RIZZO A, Salari F, Galli C, Maffeo M, et al
   Integrated Hospital, Emergency Department, and Community Surveillance for Respiratory Viruses in Milan, Italy.
   J Med Virol. 2026;98:e71073.
   PubMed         Abstract available
   
   
10. JAVED A, Hayat J, Haider SA, Jamal Z, et al
    Molecular Surveillance and Genomic Characterization of Influenza A(H3N2) Viruses From a Secondary-Care Surveillance Site in Pakistan During the 2025-2026 Winter Season.
    J Med Virol. 2026;98:e71075.
    PubMed         Abstract available
    
    

    
    J Virol

11. HERNANDEZ PC, Moeller NH, Aihara H
    Distinct modes of RNA degradation by the structurally related coronavirus and arenavirus exoribonucleases.
    J Virol. 2026 Jul 23:e0079826. doi: 10.1128/jvi.00798.
    PubMed         Abstract available
    
    
12. LIU X, Wang L, Liu Y, Xiong M, et al
    Single-cell RNA sequencing identifies uterine stromal cells as a previously unrecognized target of an alphacoronavirus underlying reproductive disorders.
    J Virol. 2026 Jul 22:e0023726. doi: 10.1128/jvi.00237.
    PubMed         Abstract available
    
    
13. XU Y, Mou C, Xiang Y, Liu H, et al
    HERPUD1 suppresses porcine epidemic diarrhea virus replication by recruiting HRD1 to degrade viral ORF3 protein.
    J Virol. 2026;100:e0062626.
    PubMed         Abstract available
    
    
14. BEETON K, Case JB
    Respiratory mucosal vaccines for emerging viruses: promise and challenges.
    J Virol. 2026 Jul 23:e0174825. doi: 10.1128/jvi.01748.
    PubMed         Abstract available
    
    
15. FANG P, Xiao W, Wang X, Xiong Y, et al
    Identification of TMEM41B TM6 as a critical domain for coronavirus replication in vitro and in vivo.
    J Virol. 2026 Jul 24:e0049326. doi: 10.1128/jvi.00493.
    PubMed         Abstract available
    
    

    
    JAMA

16. CAMILLERI M
    Gastroparesis: A Review.
    JAMA. 2026 Jul 22. doi: 10.1001/jama.2026.12181.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

17. HOFFMANN M, Shandheep A, Pavlou A, Rahmel-Stein K, et al
    Pseudovirus-based analysis of host cell entry and vaccine-induced neutralisation of Bundibugyo virus.
    Lancet Infect Dis. 2026 Jul 23:S1473-3099(26)00407.
    PubMed        
    
    
18. WU M, Hong H, Guo Y, Daniel K, et al
    SARS-CoV-2 BA.3.2.2 is more evasive of neutralisation by plasma from young children.
    Lancet Infect Dis. 2026 Jul 22:S1473-3099(26)00349.
    PubMed        
    
    
19. ONYEAGHALA C
    A defining clinical moment during the COVID-19 pandemic in Nigeria.
    Lancet Infect Dis. 2026;26:e277.
    PubMed        
    
    
20. AHMAD N, Ure R, MacDonald L, Keegan S, et al
    Genomic epidemiology of invasive meningococcal disease in Scotland before, during, and after the COVID-19 pandemic: a retrospective observational study.
    Lancet Infect Dis. 2026 Jul 21:S1473-3099(26)00284.
    PubMed         Abstract available
    
    

    
    Nature

21. 
    Mapping drivers of life expectancy change in Asia from 1990 to 2023.
    Nature. 2026 Jul 22. doi: 10.1038/s41586-026-10739.
    PubMed         Abstract available
    

#Coronavirus Disease Research #References (AMEDEO, July 19 '26)

 

Clin Infect Dis

1. PAYNE DC, Weinberg GA, Halasa NB, Englund JA, et al
   The New Vaccine Surveillance Network: 25 years of active, population-based surveillance for pediatric infectious diseases in the United States.
   Clin Infect Dis. 2026 Jul 13:ciag434. doi: 10.1093.
   PubMed         Abstract available
   
   
2. MEYEROWITZ EA, Richterman A
   Hantavirus on a Cruise Ship: What COVID-19 Taught Us.
   Clin Infect Dis. 2026 Jul 11:ciag428. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Emerg Infect Dis

3. FALENDER R, Kaya D, Harry M, Hachimi O, et al
   Targeted Wastewater Surveillance during the World Athletics Championship, Oregon, USA, 2022.
   Emerg Infect Dis. 2026;32.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. AUBRY A, Brochot E, Demey B, Louchet-Ducoroy M, et al
   Epidemiological trends in viral CNS infections in a French university hospital from 2019 to 2024, as revealed by multiplex PCR testing of cerebrospinal fluid samples.
   Int J Infect Dis. 2026 Jul 12:108977. doi: 10.1016/j.ijid.2026.108977.
   PubMed         Abstract available
   
   

   
   J Infect

5. HANSEN CL, Shaikh N, Naeger S, Torcel-Pagnon L, et al
   Hospitalizations and deaths from major respiratory viruses in the US: An ensemble time series modeling study, 2016-2025.
   J Infect. 2026;93:106811.
   PubMed         Abstract available
   
   

   
   J Med Virol

6. RIZZUTO J, Amarin JZ, Polic A, Howe HL, et al
   Severe COVID-19 in Pregnant Versus Nonpregnant Women: Intensive Care Unit Outcomes and Perinatal Risks.
   J Med Virol. 2026;98:e71036.
   PubMed         Abstract available
   
   

   
   J Virol

7. LOU J, Guo Z, Chen K, Tian Y, et al
   Cyclo-C stabilizes PEX13 to inhibit porcine epidemic diarrhea virus replication by blocking pexophagy-mediated disruption of antiviral innate immunity.
   J Virol. 2026 Jul 17:e0078526. doi: 10.1128/jvi.00785.
   PubMed         Abstract available
   
   
8. OVERSTI S, Lytras S, Kawakubo S, Ito J, et al
   From sites to structure to serology: a roadmap for structure-aware molecular evolution of antigenically evolving viruses.
   J Virol. 2026 Jul 16:e0168725. doi: 10.1128/jvi.01687.
   PubMed         Abstract available
   
   
9. KAWAHARA S, Nao N, Tulakarnwong S, Suzuki S, et al
   GC content mismatch of transgene destabilizes RNA virus genomes.
   J Virol. 2026 Jul 13:e0088226. doi: 10.1128/jvi.00882.
   PubMed         Abstract available
   
   

   
   Lancet

10. CRIVELLI L, Suemoto CK, Sosa AL, Lopera F, et al
    Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.
    Lancet. 2026 Jul 13:S0140-6736(26)01278-X. doi: 10.1016/S0140-6736(26)01278.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

11. OPPEGAARD O, Blomberg B, Cox RJ, Iversen A, et al
    Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.
    Lancet Infect Dis. 2026 Jul 16:S1473-3099(26)00244.
    PubMed         Abstract available
    
    
12. NAIDOO T, Morgenstern C, Doohan P, Earl R, et al
    A systematic review of Nipah virus disease epidemiological parameters, outbreaks, and mathematical models.
    Lancet Infect Dis. 2026 Jul 14:S1473-3099(26)00239.
    PubMed         Abstract available
    
    

    
    N Engl J Med

13. WARKENTIN TE, Greinacher A
    Platelet-Activating Anti-Platelet Factor 4 Disorders.
    N Engl J Med. 2026 Jul 13. doi: 10.1056/NEJMra2502459.
    PubMed         Abstract available
    
    

    
    Nature

14. 
    Party pooper: grandparents' COVID risk rose after grandchildren's birthdays.
    Nature. 2026 Jul 13. doi: 10.1038/d41586-026-02194.
    PubMed        
    
    
15. GULLAND A
    This microbiologist endured a four-year court battle over COVID-19 tests.
    Nature. 2026 Jul 13. doi: 10.1038/d41586-026-01654.
    PubMed        
    

#Coronavirus Disease Research #References (AMEDEO, July 11 '26)

 

Am J Respir Crit Care Med

1. JERRETT M, Nau CL, Young DR, Butler RK, et al
   Association Between Air Pollution and Post Acute Sequelae of SARS-CoV-2 (PASC).
   Am J Respir Crit Care Med. 2026 Jul 3:aamag341. doi: 10.1093.
   PubMed        
   
   

   
   Ann Intern Med

2. DARNALL BD, Perez L, Kao MC, Lorig K, et al
   Patient-Centered Prescription Opioid Tapering Methods : A Randomized Clinical Trial.
   Ann Intern Med. 2026 Jul 7. doi: 10.7326/ANNALS-25-04784.
   PubMed         Abstract available
   
   

   
   BMJ

3. HAQ ZU
   Ebola control is weakened by mistrust and cultural insensitivity.
   BMJ. 2026;394:e100190.
   PubMed        
   
   

   
   Clin Infect Dis

4. ROSTER KIO, White PJ, Grad YH
   Why Are Gonorrhea Case Rates Declining in the United States? A Research Agenda.
   Clin Infect Dis. 2026;82:1082-1090.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. MIYAKAWA K, Sano K, Seki Y, Sato R, et al
   Cross-neutralization of SARS-CoV-2 BA.3.2.2 lineage by JN.1 mRNA vaccine-induced immunity.
   Int J Infect Dis. 2026 Jul 4:108954. doi: 10.1016/j.ijid.2026.108954.
   PubMed         Abstract available
   
   
6. JO Y, Hu Z, Joo H, Jung J, et al
   Time to Recovery from Long COVID: A Longitudinal Analysis of Symptom Duration and Risk Factors Using Accelerated Failure Time Models.
   Int J Infect Dis. 2026 Jul 5:108963. doi: 10.1016/j.ijid.2026.108963.
   PubMed         Abstract available
   
   
7. CHUI CSL, Lau JC, Fan M, Chan BP, et al
   Concurrent comparison of severity of influenza and COVID-19 among hospitalized patients in Hong Kong: a target trial emulation on observational healthcare data.
   Int J Infect Dis. 2026 Jul 7:108958. doi: 10.1016/j.ijid.2026.108958.
   PubMed         Abstract available
   
   
8. JABER F, Rawas SE, Faraj S, Zoghby LA, et al
   Value of the Pitt bacteremia score in predicting the outcome of non-bacteremic patients with infections caused by multidrug-resistant organisms.
   Int J Infect Dis. 2026 Jul 7:108960. doi: 10.1016/j.ijid.2026.108960.
   PubMed         Abstract available
   
   
9. ACANFORA D, Nolano M, Acanfora C, Colella C, et al
   Vagal cholinergic denervation of the gastric mucosa in Long-COVID-19: in vivo evidence of structural autonomic dysfunction.
   Int J Infect Dis. 2026 Jul 9:108973. doi: 10.1016/j.ijid.2026.108973.
   PubMed         Abstract available
   
   

   
   J Infect

10. VINK E, Murphy ME, Gunson R, MacConnachie A, et al
    Respiratory viral detection in adult severe acute respiratory infection post-COVID-19 pandemic: implications for antimicrobial stewardship.
    J Infect. 2026;93:106805.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. BUMBERGER AM, Kastner MT, Gawish R, Rusing L, et al
    Torque Teno Virus Dynamics in Plasma and BAL of COVID-19 ARDS Patients With and Without ECMO.
    J Med Virol. 2026;98:e71047.
    PubMed         Abstract available
    
    
12. WENINGER J, Zedginidze A, Katsounas A, Pohl M, et al
    Assessment of Residual-Serum SARS-CoV-2-N-Antigen Testing for Hospital Surveillance in Germany.
    J Med Virol. 2026;98:e71055.
    PubMed         Abstract available
    
    
13. GORIS M, Valdez M, Lamont L, Yang W, et al
    Tracking COVID-19 Severity and Progression Through Amines and Lipid Mediators.
    J Med Virol. 2026;98:e71030.
    PubMed         Abstract available
    
    
14. TUNER B, Agca H
    Molecular Types of Rhinovirus Among Cases of Acute Respiratory Infections in a University Hospital.
    J Med Virol. 2026;98:e71058.
    PubMed         Abstract available
    
    

    
    J Virol

15. LIANG Y-F, Li X, Zhu G-x, Song Y, et al
    Magnolol inhibits porcine epidemic diarrhea virus infection by suppressing cathepsin L expression in vitro and in vivo.
    J Virol. 2026 Jun 25:e0013726. doi: 10.1128/jvi.00137.
    PubMed         Abstract available
    
    
16. ZHAO Y, Zhao J, Li Y, Duan L, et al
    Disruption of the S1/S2 multibasic cleavage site attenuates infectious bronchitis virus, while S2' partially restores viral virulence and expands tissue tropism.
    J Virol. 2026 Jul 6:e0061426. doi: 10.1128/jvi.00614.
    PubMed         Abstract available
    
    
17. STEFANOS B, Green NRB, Nadig I, Lapierre LA, et al
    Coronavirus membrane protein with a fluorescent protein tag enables particle tracking for the study of virus assembly and egress in live cells.
    J Virol. 2026 Jul 6:e0222825. doi: 10.1128/jvi.02228.
    PubMed         Abstract available
    
    
18. ZHOU R, Yue M, Shen Q, Liu N, et al
    Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes.
    J Virol. 2026 Jul 9:e0040126. doi: 10.1128/jvi.00401.
    PubMed         Abstract available
    
    

    
    Lancet

19. DEZZA FC, Pulido LB, Borreguero IB, Perez FD, et al
    Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTE): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.
    Lancet. 2026 Jul 9:S0140-6736(26)00760-9. doi: 10.1016/S0140-6736(26)00760.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

20. 
    Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial.
    Lancet Infect Dis. 2026 Jul 8:S1473-3099(26)00242.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

21. PATRICK R, Lee K, Kuan M, Chan M, et al
    Norovirus, COVID-19, and Influenza Outbreaks Among Residents and Staff Members at the Eaton Wildfire Evacuation Shelter - Pasadena, California, January-February 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:337-342.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, July 5 '26)

 

Ann Intern Med

1. XIE Y, Choi T, Al-Aly Z
   Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00217.
   PubMed         Abstract available
   
   
2. 
   Summary for Patients: Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00217.
   PubMed        
   
   

   
   BMJ

3. COZZOLINO A
   Covid-19 vaccine study pulled by US CDC is finally published.
   BMJ. 2026;394:e100157.
   PubMed        
   
   

   
   J Infect

4. RAN J, Zhu L, Ning M, Zhang W, et al
   Age-associated impairment of humoral and cellular immune responses to SARS-CoV-2 in a large community cohort with hybrid immunity.
   J Infect. 2026 Jul 1:106803. doi: 10.1016/j.jinf.2026.106803.
   PubMed         Abstract available
   
   

   
   J Med Virol

5. WIDANAGAMAACHCHI WN, Callahan AR, Willson TM, Barbeau B, et al
   How Many Veteran COVID-19 Cases Were There during the Pandemic?
   J Med Virol. 2026;98:e71040.
   PubMed         Abstract available
   
   

   
   J Travel Med

6. KASSIANOS G, Goodyer L, Gomensoro EEB, Doobaree U, et al
   Assessment of the healthcare burden of dengue disease in England: a retrospective analysis (2010-2023).
   J Travel Med. 2026 Jul 2:taag059. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

7. ZHOU X, Ivanov KI, Ge X, Guo X, et al
   Identification of GRP78 as a novel host factor that facilitates zoonotic porcine deltacoronavirus internalization and replication via clathrin-mediated endocytosis.
   J Virol. 2026 Jul 2:e0071726. doi: 10.1128/jvi.00717.
   PubMed         Abstract available
   
   
8. TIWAREKAR V, Ebenig A, Predota Y, Schrauf S, et al
   Minor differences in the untranslated regions of measles vector additional transcription units are reflected by differential immunogenicity of encoded MERS-CoV Spike antigen.
   J Virol. 2026 Jul 1:e0064426. doi: 10.1128/jvi.00644.
   PubMed         Abstract available
   
   
9. ZHANG L, Li Y, Zhao J, Liang R, et al
   Characterization of nucleolar localization signals in the avian infectious bronchitis virus nucleocapsid protein and their critical role in viral replication.
   J Virol. 2026;100:e0043326.
   PubMed         Abstract available
   
   

   
   JAMA

10. LEUNG PB, Davis AM, Marks KM
    Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection.
    JAMA. 2026 Jun 30. doi: 10.1001/jama.2026.6918.
    PubMed        
    
    

    
    Lancet

11. BLAKNEY AK, Top KA, Cowling BJ, Larson HJ, et al
    Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.
    Lancet. 2026 Jun 30:S0140-6736(26)00512-X. doi: 10.1016/S0140-6736(26)00512.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, June 27 '26)

 

Antiviral Res

1. WANG W, Wang S, Meng X, Zhao Y, et al
   Corrigendum to "A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2" [Antivir. Res. 225 (2024) 105854].
   Antiviral Res. 2026 Jun 22:106465. doi: 10.1016/j.antiviral.2026.106465.
   PubMed        
   
   
2. ZHANG G, Deng F, Luo Y, Chen J, et al
   ITGA4 drives pathogenesis of flavivirus and inhibition of it protects mice against Japanese encephalitis virus infection.
   Antiviral Res. 2026;252:106471.
   PubMed         Abstract available
   
   

   
   BMJ

3. BONVOISIN T, Todsen AL, Perinpanathan T
   Deeper understanding of healthcare system "overwhelm" during covid-19 is essential for coherent pandemic strategy.
   BMJ. 2026;393:e100006.
   PubMed        
   
   

   
   Int J Infect Dis

4. ZHANG H, Xiang C, Mu Y, Gu X, et al
   Association of acute-phase corticosteroid use with SARS-CoV-2 reinfection among hospitalized COVID-19 survivors:a 3-year follow-up study.
   Int J Infect Dis. 2026 Jun 19:108903. doi: 10.1016/j.ijid.2026.108903.
   PubMed         Abstract available
   
   
5. VAN WEELDEN G, Rabie H, Redfern A, Barday MA, et al
   Evaluating Mucosal and Systemic Immunity in an Observational Cohort of South African Children Hospitalised with Acute Respiratory Tract Infections.
   Int J Infect Dis. 2026 Jun 20:108902. doi: 10.1016/j.ijid.2026.108902.
   PubMed         Abstract available
   
   
6. VAN BILSEN CJA, Wijnen SMCE, Pagen DME, Hoebe CJPA, et al
   Workforce exit and work productivity loss in adults with and without post-COVID-19 condition: the PRIME post-COVID cohort study.
   Int J Infect Dis. 2026 Jun 23:108913. doi: 10.1016/j.ijid.2026.108913.
   PubMed         Abstract available
   
   
7. JUBAIR M, Begum MN, Samia NSN, Alam MS, et al
   Epidemiological and Genomic Surveillance of Influenza virus A, RSV B and SARS-CoV-2 in Bangladesh (2022-2024).
   Int J Infect Dis. 2026 Jun 24:108910. doi: 10.1016/j.ijid.2026.108910.
   PubMed         Abstract available
   
   
8. ENA N, Garcia-Abellan J, Ledesma C, Fernandez-Gonzalez M, et al
   Low prevalence of bacterial coinfection at hospital admission in COVID-19 and the role of procalcitonin as a rule-out biomarker (Revised Version).
   Int J Infect Dis. 2026 Jun 25:108925. doi: 10.1016/j.ijid.2026.108925.
   PubMed         Abstract available
   
   
9. QUEK AML, Ooi DSQ, Teng O, Foon CH, et al
   Adiposity shapes the immune architecture independent of antibody responses in mild SARS-CoV-2 Infection.
   Int J Infect Dis. 2026 Jun 26:108932. doi: 10.1016/j.ijid.2026.108932.
   PubMed         Abstract available
   
   
10. WAKAMATSU K, Tananari Y, Nakamura K, Nakamura T, et al
    Oropharyngeal swabs show higher bacterial loads than nasopharyngeal swabs for PCR detection of pertussis: a multicenter prospective study.
    Int J Infect Dis. 2026 Jun 26:108937. doi: 10.1016/j.ijid.2026.108937.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. HELAL A, Aljehani ND, Ghazwani A, Alsulaiman RM, et al
    Broadly Protective Antibody-Like Vaccines Against Highly Pathogenic Coronaviruses.
    J Med Virol. 2026;98:e71008.
    PubMed         Abstract available
    
    
12. SILVA RMD, Soper MS, Neves JH, Maciel CEA, et al
    Association Between Inflammatory Markers, Comorbidities, and Mortality in COVID-19 Patients Treated With Tocilizumab.
    J Med Virol. 2026;98:e71028.
    PubMed         Abstract available
    
    
13. FOURIE E, van Leeuwen LM, Euser SM, Wildenbeest JG, et al
    Long-Term Dynamics of Pediatric Respiratory Pathogens Before, During, and After the COVID-19 Pandemic: Evidence From Nine Years of Surveillance in the Netherlands (2015-2023).
    J Med Virol. 2026;98:e71022.
    PubMed         Abstract available
    
    
14. MOHI UD DIN MALIK M, Saraf A, Bhrushundi MP
    Comment on "Prevalence and Risk Factors for Persistent Post-COVID-19 Condition at 3, 6, 12, and 18 Months After Initial Infection Among Adults Living in a Community of Japan: Yao COVID-19 Study".
    J Med Virol. 2026;98:e71041.
    PubMed        
    
    
15. NABEYA D, Kinjo T, Nishiyama N, Kami W, et al
    Virus-Specific Impact of Respiratory Viruses on Adult Emergency Department Outcomes.
    J Med Virol. 2026;98:e71039.
    PubMed         Abstract available
    
    

    
    J Virol

16. BERMEJO-JAMBRINA M, Pauzuolis M, Kimpel J, Gerold G, et al
    Double trouble: how co- and superinfections shape viral dynamics and host responses.
    J Virol. 2026 Jun 23:e0205525. doi: 10.1128/jvi.02055.
    PubMed         Abstract available
    
    

    
    N Engl J Med

17. RUELLA M, Paruzzo L, Chong ER, Chong EA, et al
    Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
    N Engl J Med. 2026;394:2440-2448.
    PubMed         Abstract available
    
    

    
    Nature

18. LOCCI M, Pardi N
    Immunological mechanisms of mRNA vaccines for infectious diseases.
    Nature. 2026;654:892-901.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

19. SHU HJ, Chang ST, Gameiro RR, Gichoya JW, et al
    Impact of Exposure Parameters on Deep Learning Models in Chest Radiography and Implications for Deployment.
    Radiol Artif Intell. 2026 Jun 24:e250731. doi: 10.1148/ryai.250731.
    PubMed         Abstract available